Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Behcet's syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Amgen; Celgene Corporation

Most Recent Events

  • 09 Nov 2021 Results of subgroup analysis assessing consistency of efficacy of apremilast in men and women presented at the ACR Convergence 2021
  • 01 Sep 2021 Results of extension phase study assessing long-term outcomes over 68 weeks from this trial published in the Clinical and Experimental Rheumatology
  • 05 Jun 2021 Results evaluating the consistency of efficacy with APR in men and women to treat oral ulcers (OU) associated with Behcet's syndrome presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top